دورية أكاديمية

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)

التفاصيل البيبلوغرافية
العنوان: Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
المؤلفون: Agarwal, Neeraj *, McGregor, Bradley, Maughan, Benjamin L, Dorff, Tanya B, Kelly, William, Fang, Bruno, McKay, Rana R, Singh, Parminder, Pagliaro, Lance, Dreicer, Robert, Srinivas, Sandy, Loriot, Yohann, Vaishampayan, Ulka, Goel, Sanjay, Curran, Dominic, Panneerselvam, Ashok, Schwickart, Martin, Choueiri, Toni K *, Pal, Sumanta *
المصدر: In The Lancet Oncology July 2022 23(7):899-909
قاعدة البيانات: ScienceDirect
الوصف
تدمد:14702045
DOI:10.1016/S1470-2045(22)00278-9